HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA nanotech public meeting

This article was originally published in The Rose Sheet

Executive Summary

In reviewing findings of FDA's nanotechnology task force that prompted Sept. 8 public meeting, FDA's Richard A. Canady, Ph.D., Office of the Commissioner, stressed that since "nanotechnology and its application within new products is an emerging technology ... we're really looking forward to your input." Agency will have to wait, as Personal Care Products Council revealed it is still preparing its comments for Oct. 24 deadline set by FDA, which seeks information on nanoscale materials in order to develop industry guidance. During cosmetics-specific breakout session, FDA's five questions for manufacturers - including "What characteristics or types of nanoscale materials would be important to specify when considering potential risks of cosmetic products?" and "What, if any, additional studies are done for a product containing nanoscale particles to prove that this type of formulation is safe?" - received no feedback (1"The Rose Sheet" Aug. 25, 2008, p. 8). In absence of "clear, transparent regulatory pathway," Canady encouraged companies developing nanotechnology-based products to consult with the agency early on. "It may be important to come in and interact for example with our Office of Combination Products to consider pathways that might work best for evaluation of the product," he said

You may also be interested in...



FDA Curious About Safety Measures Taken By Cosmetic Firms Using Nanotech

At an upcoming public meeting FDA will seek perspective from personal-care manufacturers that work with nano-scale materials on the measures taken to ensure that products containing such materials are safe

On CRN Challenge, Nexus Formulas Gets Lesson On Supporting Ad Claims For Supplements

So full of errors were the firm's online ads for its Plavinol supplement, the National Advertising Division noted support for some claims contained "many of the same flaws" as others. The prevalence of problems prompted NAD to go its "scope of review" and note unclear instructions on Plavinol labels.

FDA’s Cannabidiol Crackdown: What Do Warning Letters Say About CBD In Cosmetics?

Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.

UsernamePublicRestriction

Register

RS015660

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel